touchIMMUNOLOGY were delighted to speak with Prof. Maarten Boers (Amsterdam University Medical Center, Amsterdam, The Netherlands) to discuss the GLORIA trial, investigating the benefits and harms of long term add-on low dose prednisolone in rheumatoid arthritis.
The abstract ‘Favorable balance of benefit and harm of long-term, low dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: The pragmatic, multicenter, placebo- controlled GLORIA trial.’ (Abstract number: OP0263) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
- What is known about the benefits and harms of long term, low dose glucocorticoid therapy in rheumatoid arthritis (RA), and what questions remain unanswered? (0:18)
- What were the objectives and methodology of the GLORIA trial? (1:22)
- What were the findings of the study in terms of benefits and harms? (1:57)
- What were the conclusions of the investigators regarding future use of add-on low dose prednisolone in RA? (4:14)
- Which patients are most likely to benefit from this approach and in whom is it contraindicated? (5:52)
Disclosures: Maarten Boers discloses consulting for Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Clare Jacklin: Rheumatoid Arthritis Awareness Week 2022
It was a pleasure to talk with Clare Jacklin, CEO of the National Rheumatoid Arthritis Society (NRAS) around the goals of the Rheumatoid Arthritis Awareness Week (RAAW) taking place from 12-17 September, and the importance of RAAW in raising physician and patient awareness of RA to improve disease outcomes. Questions What are the goals of […]
Clare Jacklin: The National Rheumatoid Arthritis Society
With RA Awareness Week taking place in September, touchIMMUNOLOGY were delighted to speak with Clare Jacklin, CEO of the National Rheumatoid Arthritis Society (NRAS) to learn more around the aims of the society, the importance of being a patient-led organisation and of increasing public understanding to reduce misconceptions around RA. Questions What are the key […]
Axel Finckh, EULAR 2022: Findings from the “JAK-pot” Study
The “JAK-pot” study compared the safety of JAK inhibitors (JAKis) to other biologic agents in the treatment of patients with rheumatoid arthritis (RA). touchIMMUNOLOGY were delighted to speak with Prof. Axel Finckh (University of Geneva, Geneva, Switzerland) to discuss real world safety and tolerability of JAKis and treatment discontinuation for JAKis compared to other treatments […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!